PMEL and melanoma: A major breakthrough in the immunotherapeutic landscape for mUM came with the recent FDA approval of tebentafusp (IMCgp100), a bispecific T cell engager that targets gp100 presented by HLA-A02:01 and recruits polyclonal T cells to kill melanoma cells.